ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

The risk of developing postoperative venous thromboembolism (VTE) is very high for patients undergoing hip fracture or other major orthopaedic surgery. Deep vein thrombosis (DVT) or pulmonary embolism (PE) can result, and the latter is often fatal. In addition, subsequent complications, including recurrences and ongoing post-thrombotic syndrome (PTS) can prove costly and resource intensive. Low molecular weight heparins, such as enoxaparin sodium, are widely used for routine prophylaxis among these patients. However, recently, the novel pentasaccharide fondaparinux sodium [Arixtra] has been approved for VTE prophylaxis among patients undergoing orthopaedic surgery, and has proven to be more effective than enoxaparin in preventing VTE after hip fracture surgery. The number of patients undergoing hip fracture surgery is rising, in part due to the ageing population worldwide. Thus, assessment of the clinical and economic effects of introducing fondaparinux into clinical practice is of significant value to physicians and healthcare providers. Several studies examining these issues were presented at a large poster session at the 6th Annual European Conference of the International Society of Pharmacoeconomics and Outcomes Research [ISPOR, Nov 2003; Barcelona, Spain].

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Abetimus [LJP 394, Riquent] is a novel immunomodulating agent specifically designed to reduce the generation of antibodies to double-stranded DNA (dsDNA) without suppressing normal immune function. These antibodies are believed to be responsible for the development of lupus nephritis, a chronic kidney disease, in patients with systemic lupus erythematosus (SLE). According to studies presented at the 67th Annual Scientific Meeting of the American College of Rheumatology [Orlando, US; October 2003], abetimus is well tolerated and may reduce the incidence of renal flares and major disease flares in patients with SLE. Results from phase II/III and phase III studies presented at the meeting confirmed earlier clinical data showing that abetimus significantly reduces anti-dsDNA antibodies, and that this reduction in antibody levels correlates with lower incidences of renal flares.1,2Furthermore, reductions in antibody levels were associated with improvement in health-related quality of life (HRQOL).

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS